AVDL Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own AVDL shares is 230, representing 80.6% of the company's common stock.

GOLDMAN SACHS GROUP INC, in the last quarter, reduced its stake in AVDL by -23.2% restricting it's holding to 374.2 thousand shares of worth nearly $6.32M. RENAISSANCE TECHNOLOGIES LLC also lessened -35.05% of the AVDL shares from its portfolio, reducing its holding to 406.01 thousand shares of worth $6.86M. MORGAN STANLEY also shunned AVDL shares holding by -32.92% last quarter which brought its holding to 665.41 thousand shares worth $11.24M.

As per its latest 13F filing, PARKMAN HEALTHCARE PARTNERS LLC increased its stake in AVDL by 100% in the last quarter. The institutional holder raised its holding to 387.77 thousand shares having worth more than $6.55M. NEW YORK STATE COMMON RETIREMENT FUND also added 100% more shares of AVDL to its portfolio, raising its holding to 399.55 thousand shares of worth $6.75M. ALLY BRIDGE GROUP (NY) LLC also increased its AVDL shares holding by 57.63% which brought its holding to 547.04 thousand shares worth $9.24M.

The insider with the most stakes in AVDL is Broadfin Healthcare Master Fund Ltd , 10 percent owner at the company. Additionally, AVDL stock is highly held by 10 percent owner Flynn James E and Chief Executive Officer ANDERSON MICHAEL S among others.

Company executives, directors, and other insiders own 4.78% percent of Avadel Pharmaceuticals plc's stock. Within the last six months, there have been 0 transaction(s) in which AVDL insiders have sold stock, totaling 0 shares. Insiders that have sold shares include MCCAMISH MARK ANTHONY, HATTEN SANDRA L, and GUSKY DAVID P.

There have been 8 transaction(s) during the past 6-months in which Avadel Pharmaceuticals plc insiders have bought stock, totalling 70375 shares

Around 641.33K Avadel Pharmaceuticals plc shares are held by insiders, which represents about 4.78% of AVDL stock.

AVDL 10 percent owner, Broadfin Healthcare Master Fund Ltd holds the largest portfolio of the company's shares. AVDL shares owned by Broadfin total nearly 4.13 million.

GOLDMAN SACHS GROUP INC is the largest institutional owner in AVDL which holds 374.2 thousand shares worth $6.32M or 0.47% of the total AVDL shares outstanding followed by PARKMAN HEALTHCARE PARTNERS LLC with ownership of 387.77 thousand shares representing 0.48% of the AVDL ownership. NEW YORK STATE COMMON RETIREMENT FUND is the third largest stakeholder with 399.55 thousand shares or 0.5% of the ownership worth more than $6.75M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the AVDL is concerned, it is a stock which is optionable.

Number of AVDL shares short is 11.77M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 96.36M shares of AVDL are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, AVDL has 83.31M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for AVDL is 10.87.